Search

Displaying results 2491 - 2500 of 10000 in total
  1. Target

    Prolyl 3-hydroxylase 1

    go.drugbank.com/bio_entities/BE0002202
    TargetEnzymeHumans

    Has prolyl 3-hydroxylase activity and catalyzes the post-translational formation of 3-hydroxyproline in -Xaa-Pro-Gly- sequences in pro-collagen chains, a critical step for the formation of mature collagen

    Synonyms: Leucine- and proline-enriched proteoglycan 1
  2. Drug

    Ademetionine

    go.drugbank.com/drugs/DB00118
    ApprovedInvestigationalNutraceutical

    It possesses anti-inflammatory activity and has been used in treatment of chronic liver disease. (From Merck, 11th ed) … Physiologic methyl radical donor involved in enzymatic transmethylation reactions and present in all living organisms.

    Categories: Amino Acids and Derivatives, Alimentary Tract and Metabolism
  3. Drug

    Serdexmethylphenidate

    go.drugbank.com/drugs/DB16629
    Approved

    [A230698, A230703] The underlying cause of ADHD is unclear but likely involves dysfunction in dopaminergic and noradrenergic neurotransmission, as evidenced by the clear beneficial effect of CNS stimulants … Attention Deficit Hyperactivity Disorder (ADHD) is an early-onset neurodevelopmental disorder that often extends into adulthood and is characterized by developmentally inappropriate and impaired attention

    Categories: dexmethylphenidate and serdexmethylphenidate, Psychostimulants, Agents Used for ADHD and Nootropics
  4. Drug

    Crinecerfont

    go.drugbank.com/drugs/DB18518
    ApprovedInvestigational

    [A264818] The majority of the poor health outcomes in patients with CAH result from the inability to precisely titrate glucocorticoid dosages to both adequately replace the deficiency and sufficiently … [A264818] Standard therapy involves cortisol replacement, but typically requires supraphysiological glucocorticoid doses to lower both ACTH and adrenal androgens, resulting in chronic glucocorticoid overexposure

  5. Drug

    Ixekizumab

    go.drugbank.com/drugs/DB11569
    ApprovedInvestigational

    Ixekizumab is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (mAb) against interleukin-17A (IL-17A) and prevents it from interacting with the IL-17A receptor. … Ixekizumab is produced by recombinant DNA technology in a recombinant mammalian cell line and purified using standard technology for bioprocessing.

    Categories: Amino Acids, Peptides, and Proteins, Skin and Mucous Membrane AgentsProducts: Taltz 80mg solution for injection in pre-filled pen, Taltz 80mg solution for injection in pre-filled syringe
  6. Drug

    Proline

    go.drugbank.com/drugs/DB00172
    ApprovedInvestigationalNutraceutical

    Proline is a non-essential amino acid that is synthesized from glutamic acid. It is an essential component of collagen and is important for proper functioning of joints and tendons. … Proline is sometimes called an imino acid, although the IUPAC definition of an imine requires a carbon-nitrogen double bond.

    Mixtures: Aminosyn II and Dextrose, Aminosyn II and DextroseCategories: Amino Acids, Peptides, and Proteins
  7. Drug

    Cerivastatin

    go.drugbank.com/drugs/DB00439
    ApprovedWithdrawn

    Food and Drug Administration (FDA) announced that Bayer Pharmaceutical Division voluntarily withdrew Baycol from the U.S. market, due to reports of fatal rhabdomyolysis, a severe adverse reaction from … It has also been withdrawn from the Canadian market.[A669,L43942]

  8. Drug

    Chymopapain

    go.drugbank.com/drugs/DB06752
    ApprovedWithdrawn

    Chymopapain was first isolated in 1941 from the crude latex derived from the fruit of Carica papaya by squeezing the green papaya while on the plant prior to harvest. … [L2482]It is an extracellular plant cysteine proteinase similar to papain in specificity.[A32688] Chymopapain was developed by Chart Medcl and FDA approved on November 10, 1982.

    Categories: Enzymes and Coenzymes
  9. Drug

    Vigabatrin

    go.drugbank.com/drugs/DB01080
    ApprovedInvestigational

    [A202124] Its use is now generally reserved for patients who have failed alternative therapies, and its US approval by the FDA in 2009 mandated the creation of a drug registry to monitor patients for visual … [A202037] It was first introduced as an antiepileptic agent in the United Kingdom in 1989 and was used extensively until 1997, when an association with vision loss became apparent.

  10. Drug

    Sorafenib

    go.drugbank.com/drugs/DB00398
    ApprovedInvestigational

    [A255852] First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also indicated to treat renal carcinoma and differentiated thyroid carcinoma … Sorafenib is a bi-aryl urea and an oral multikinase inhibitor.

    Categories: Antineoplastic and Immunomodulating Agents